ð ç« æ«éèš
- M. tuberculosis â slow-growing AFB, intracellular, airborne
- å
šç leading single infectious killer (1.3M deaths/yr)
- Risk activation: HIV, DM, CKD, anti-TNF, transplant, malnutrition
- Pulmonary: reactivation upper-lobe cavitary, productive cough, hemoptysis, night sweats, weight loss
- EPTB: scrofula (cervical LN), pleural (ADA), GU (sterile pyuria), Pott (spine), TB meningitis, pericardial
- Dx: GeneXpert MTB/RIF (1-2 hr) + AFB + culture; IGRA for LTBI
- Treatment:
- Drug-sensitive: 6-month RIPE OR 2024 WHO 4-month regimen (rifapentine + moxifloxacin + INH + PZA)
- MDR/Pre-XDR/XDR: BPaL/BPaLM Ã 6 mo (game changer)
- CNS: 9-12 mo + steroid
- LTBI: 3HP (INH + rifapentine weekly à 12), 4R, or 9H
- BCG: efficacy child TB meningitis/miliary; not adult pulmonary
- ç§é«åž« hint: DM + è + æ
¢æ§ cough / weight loss â suspect TB; rifampin + ç³è¥ / DOAC / ART éœæ interaction